Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2] thiazolo[5,4- d ]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent

Journal of Medicinal Chemistry

Volumn 54, Issue 19, 2011, Pages 6734-6750

  Theoclitou, Maria Elena ^a   Aquila, Brian ^a   Block, Michael H ^a   Brassil, Patrick J ^a   Castriotta, Lillian ^a   Code, Erin ^a   Collins, Michael P ^a   Davies, Audrey M ^a   Deegan, Tracy ^a   Ezhuthachan, Jayachandran ^a   Filla, Sandra ^a,b   Freed, Ellen ^a,c   Hu, Haiqing ^a   Huszar, Dennis ^a   Jayaraman, Muthusamy ^d   Lawson, Deborah ^a   Lewis, Paula M ^a   Nadella, Murali V P ^a   Oza, Vibha ^a   Padmanilayam, Maniyan ^d   Pontz, Timothy ^a   Ronco, Lucienne ^a   Russell, Daniel ^a   Whitston, David ^a   Zheng, Xiaolan ^a   more..

^a ASTRAZENECA   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d ORGANIX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 4877; KINESIN SPINDLE PROTEIN INHIBITOR; N (3 AMINOPROPYL) N [1 (5 BENZYL 3 METHYL 4 OXO [1,2]THIAZOLO[5,4 D]PYRIMIDIN 6 YL) 2 METHYLPROPYL] 4 METHYLBENZAMIDE; N (3 AMINOPROPYL) N [1 (5 BENZYL 3 METHYL 4 OXO [1,2]THIAZOLO[5,4 D]PYRIMIDIN 6 YL) PROPYL] 4 METHYLBENZAMIDE; N (3 AMINOPROPYL) N [1 (5 BENZYL 3 METHYL 4 OXO [1,2]THIAZOLO[5,4 D]PYRIMIDIN 6 YL)PROPYL] 3 FLUORO 4 METHYLBENZAMIDE; N (3 AMINOPROPYL) N [1 (5 BENZYL 3 METHYL 4 OXO [1,2]THIAZOLO[5,4 D]PYRIMIDIN 6 YL)PROPYL] 4 BROMOBENZAMIDE; N (3 AMINOPROPYL) N [1 [5 [(3 FLUOROPHENYL)METHYL] 3 METHYL 4 OXO [1,2]THIAZOLO[5,4 D]PYRIMIDIN 6 YL)PROPYL] 4 METHYLBENZAMIDE; N (3 AMINOPROPYL) N [1 [5 [(3 FLUOROPHENYL)METHYL] 3 METHYL 4 OXO [1,2]THIAZOLO[5,4 D]PYRIMIDIN 6 YL] 2 METHYLPROPYL] 4 METHYLBENZAMIDE; N (3 AMINOPROPYL) N [1 [5 [(4 FLUOROPHENYL)METHYL] 3 METHYL 4 OXO [1,2]THIAZOLO[5,4 D]PYRIMIDIN 6 YL] 2 METHYLPROPYL] 4 METHYLBENZAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BROMINATION; CELL CYCLE ARREST; CELL DEATH; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPOPHILICITY; MALE; MITOSIS; MOUSE; NONHUMAN; RAT; SPINDLE CELL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; BLOOD PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; HEPATOCYTES; HUMANS; KINESIN; M PHASE CELL CYCLE CHECKPOINTS; MICE; MICE, NUDE; MICROSOMES, LIVER; PROTEIN BINDING; PYRIMIDINONES; RATS; RATS, WISTAR; SOLUBILITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80053894934     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200629m     Document Type: Article

References (45)

1. Rowinski, E. K.; Onetto, N.; Canetta Renzo, M.; Arbuck, S. G. Taxol: the first of the taxanes, an important new class of antitumor agents Semin. Oncol. 1992, 19, 646-662 (Pubitemid 23004842)
2. Chabner, B. A.; Ryan, D. P.; Paz-Ares, L.; Garcia-Carbonero, R.; Calabresi, P. Antineoplastic agents. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10 th ed.; Hardman, J. G.; Limbird, L. E.; Gilman, A. G., Eds.; The MacGraw-Hill Companies, Inc.: 2001.
3. Blagosklonny, M. V.; Fojo, T. Molecular effects of paclitaxel: myths and reality (a critical review) Int. J. Cancer 1999, 83, 151-156 (Pubitemid 29449089)
4. Samson, F. E., Jr. Mechanism of axoplasmic transport J. Neurobiol. 1971, 2, 347-360
5. Chan, S. Y.; Worth, R.; Ochs, S. Block of axoplasmic transport in vitro by Vinca alkaloids J. Neurobiol. 1980, 11, 251-264 (Pubitemid 10155299)
6. Orr, G. A.; Verdier-Pinard, P.; McDaid, H. M.; Horwitz, S. B. Mechanisms of Taxol Resistance Related to Microtubules Oncogene 2003, 22, 7280-7295 (Pubitemid 37487160)
7. Gottesman, M. M. Mechanisms of cancer drug resistance Annu. Rev. Med. 2002, 53, 615-627 (Pubitemid 34177898)
8. Jordan, M. A.; Wilson, L. Microtubules as target for anticancer drugs Nat. Rev. Cancer 2004, 4, 253-265
9. Sablin, E. P. Kinesins and microtubules: their structures and motor mechanisms Curr. Opin. Cell. Biol. 2000, 12, 35-41 (Pubitemid 30095267)
10. Schief, W. R.; Howard, J. Conformational changes during kinesin motility Curr. Opin. Cell. Biol. 2001, 13, 19-28 (Pubitemid 32119288)
11. Blangy, A.; Lane, H. A.; d'Herin, P.; Harper, M.; Kress, M.; Nigg, E. A. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo Cell 1995, 83, 1159-1169
12. Ferhat, L.; Cook, C.; Chauviere, M.; Muriel, C.; Harper, M.; Kress, M.; Lyons, G. E.; Baas, P. W. Expression of the Mitotic Motor Protein Eg5 in Postmitotic Neurons: Implications for Neuronal Development J. Neurosci. 1998, 18 (19) 7822-7835 (Pubitemid 28441022)
13. Sawin, K. E.; LeGuellec, K.; Philippe, M.; Mitchison, T. J. Mitotic spindle organization by a plus-end-directed microtubule motor Nature 1992, 359, 540-543
14. Kashina, A. S.; Rogers, G. C.; Scholey, J. M. The bimC family of kinesins: essential bipolar mitotic motors driving centrosome separation Biochem. Biophys. Acta 1997, 1357, 257-271 (Pubitemid 27303747)
15. LeGuellec, R.; Paris, J.; Couturier, A.; Roghi, C.; Philippe, M. Cloning by differential screening of a Xenopus cDNA that encodes a kinesin-related protein Mol. Cell. Biol. 1991, 11, 3395-3398
16. Heck, M. M. S.; Pereira, A.; Pesavento, P.; Yannoni, Y.; Spradling, A. C.; Goldstein, L. S. B. The kinesin-like protein KLP61F is essential for mitosis in Drosophila J. Cell Biol. 1993, 123, 665-679 (Pubitemid 23324923)
17. Castillo, A.; Morse, H. C.; Godfrey, V. L.; Naeem, R.; Justice, M. J. Overexpression of Eg5 causes genomic instability and tumor formation in mice Cancer Res. 2007, 67, 10138-10147 (Pubitemid 350070785)
18. Walczak, C. E.; Vernos, I.; Mitchison, T. J.; Karsenti, E.; Heald, R. A model for the proposed roles of different microtubule-based motor proteins in establishing spindle bipolarity Curr. Biol. 1998, 8, 903-913 (Pubitemid 28371755)
19. Mayer, T. U.; Kapoor, T. M.; Haggarty, S. J.; King, R. W.; Schreiber, S. L.; Mitchison, T. J. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen Science 1999, 286, 971-974
20. Jackson, J. R.; Patrick, D. R.; Dar, M. M.; Huang, P. S. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat. Rev. Cancer 2007, 7, 107-117 (Pubitemid 46160987)
21. Hegde, P. S.; Cogswell, J.; Carrick, K.; Jackson, J.; Wood, K. W.; Eng, W. K.; Brawner, M.; Huang, P. S.; Bergsma, D. Differential gene expression analysis of kinesin spindle protein in human solid tumors. Proc. Am. Soc. Clin. Oncol. 2003, 22, abstract 535.
22. Carter, B. Z.; Mak, D. H.; Shi, Y.; Schoeber, W. D.; Wang, R. Y.; Konopleva, M.; Koller, E.; Dean, N. M.; Andreeff, M. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance Cell Cycle 2006, 5, 2223-2229 (Pubitemid 44546558)
23. Hansen, G. M.; Justice, M. J. Activation of Hex and mEg5 by retroviral insertion may contribute to mouse B-cell leukemia Oncogene 1999, 18, 6531-6539
24. Finer, J. T.; Bergnes, G.; Feng, B.; Smith, W.; Chabala, J. C. PCT Publ., 2001, WO 01/30768.
25. Fraley, M. E.; Hartman, G. D. PCT Publ., 2003, WO 03/050122, WO 03/039460, WO 03/050064, WO 03/049678, WO 03/049679, WO 03/049527.
26. Hackney, D. D.; Jiang, W. Assays for kinesin microtubule-stimulated ATPase activity Methods Mol. Biol. 2001, 164, 65-71
27. Sorbera, L. A.; Bolos, J.; Serradell, N.; Bayes, M. Ispinesib mesilate Drugs Future 2006, 31, 778-787
28. Cox, C. D.; Breslin, M. J.; Mariano, B. J.; Coleman, P. J.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Huber, H. E.; Kohl, N. E.; Torrent, M.; Yan, Y.; Kuo, L. C.; Hartman, G. D. Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP Bioorg. Med. Chem. Lett. 2005, 15, 2041-2045 (Pubitemid 40445465)
29. Marcus, A. I.; Peters, U.; Thomas, S. L.; Garrett, S.; Zelnak, A.; Kapoor, T. M.; Giannakakou, P. Mitotic kinesin inhibitors induce mitotic arrest and cell death in taxol-resistant and -sensitive cancer cells J. Biol. Chem. 2005, 280, 11569-11577 (Pubitemid 40418469)
30. Bergnes, G.; Brejc, K.; Belmont, L. Mitotic Kinesins: Prospects for Antimitotic Drug Discovery Curr. Top. Med. Chem. 2005, 5, 127-145 (Pubitemid 40514510)
31. Sakowicz, R; Finer, J T; Beraud, C; Crompton, A; Lewis, E; Fritsch, A; Lee, Y; Mak, J; Moody, R; Turincio, R; Chabala, J. C.; Gonzales, P; Roth, S; Weitman, S; Wood, K. W. Antitumor activity of a kinesin inhibitor Cancer Res. 2004, 64, 3276-3280 (Pubitemid 38581433)
32. Hotha, S.; Yarrow, J. C.; Yang, J. G.; Garrett, S.; Renduchintala, K. V.; Mayer, T. U.; Kapoor, T. M. HR22C16: a potent small-molecule probe for the dynamics of cell division Angew. Chem., Int. Ed. 2003, 30 (42) 2379-2382 (Pubitemid 36735546)
33. Cox, C. D.; Coleman, P. J.; Breslin, M. J.; Whitman, D. B.; Garbaccio, R. M.; Fraley, M. E.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Schaber, M. D.; Lobell, R. B.; Tao, W.; Davide, J. P.; Diehl, R. E.; Abrams, M. T.; South, V. J.; Huber, H. E.; Torrent, M.; Prueksaritanont, T.; Li, C.; Slaughter, D. E.; Mahan, E.; Fernandez-Metzler, C.; Yan, Y.; Kuo, L. C.; Kohl, N. E.; Hartman, G. D. Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2S)-4-(2,5-Difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl] -2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory Cancer J. Med. Chem. 2008, 51, 4239-4252 (Pubitemid 352032448)
34. Bergnes, G.; Ha, E.; Feng, B.; Smith, W. W.; Yao, B.; Tochimoto, T.; Lewis, E. R.; Lee, Y.; Moody, R. S.; Finer, J. T.; Turinci, R. A.; Wood, K.; Sakowicz, R.; Crompton, A. M.; Chabala, J. C.; Morgans, D. J.; Sigal, N. H.; Sabry, J. H. Mitotic kinesin-targeted antitumor agents: Discovery, lead optimization and anti-tumor activity of a series of novel quinazolinones as inhibitors of kinesin spindle protein (KSP). In Abstracts of Papers, 223rd National Meeting of the American Chemical Society, Orlando, FL, United States; American Chemical Society: Washington, DC, 2002; MEDI-249.
35. McDonald, A.; Bergenes, G.; Feng, B.; Morgans, D. J. C.; Knight, S. D.; Newlander, K. A.; Dhanak, D.; Brook, C. S. PCT Publ., 2003, WO 03/088903.
36. DeBonis, S.; Skoufias, D. A.; Lebeau, L.; Lopez, R.; Robin, G.; Margolis, R. L.; Wade, R. H.; Kozielski, F. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities Mol. Cancer Ther. 2004, 3, 1079-1090 (Pubitemid 39295005)
37. Hans, J.; Wallace, E. M.; Zhao, Q.; Lyssikatos, J. P.; Aicher, T.; Laird, E.; Robinson, J.; Allen, S. PCT Publ., 2006, WO 06/044825
38. Ahrendt, K.; Delisle, R. K.; Hans, J.; Lyssikatos, J. P.; Robinson, J.; Wallace, E. M.; Zhao, Q.; PCT Publ., 2008, WO 08/042928.
39. Chin, G. M.; Herbst, R. Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint Mol. Cancer Ther. 2006, 5, 2580-2591 (Pubitemid 44650923)
40. Woessner, R.; Corrette, C.; Allen, S.; Hans, J.; Zhao, Q.; Aicher, T.; Lyssikatos, J.; Robinson, J.; Poch, G.; Hayter, L.; Cox, A.; Lee, P.; Winkler, J.; Koch, K.; Wallace, E. ARRY-520: a KSP inhibitor with efficacy and pharmacodynamic activity in animal models of solid tumors. AACR Annual Meeting, 2007.
41. Lemieux, C.; DeWolf, W.; Voegtli, W.; DeLisle, R. K.; Laird, E.; Wallace, E.; Woessner, R.; Corrette, C.; Allen, S.; Hans, J.; Zhao, Q.; Aicher, T.; Lyssikatos, J.; Robinson, J.; Koch, K.; Winkler, J.; Gross, S. ARRY-520: a novel, highly selective KSP inhibitor with potent anti-proliferative activity. AACR Annual Meeting, 2007.
42. Aquila, B.; Block, M. H.; Davies, A.; Ezhuthachan, J.; Filla, S.; Luke, R.; Pontz, T.; Theoclitou, M. E.; Zheng, X; PCT Int. Appl., 2004, WO 04/078758
43. Block, M. H.; Davies, A.; Russell, D.; Theoclitou, M. E.; PCT Int. Appl., 2006, WO 06/008523
44. Finer, J. T.; Bergnes, G.; Feng, B.; Smith, W. W.; Chabala, J.; PCT Publ., 2001, WO 01/30768 A1
45. Kantarjian, H. M.; Padmanabhan, S.; Stock, W.; Tallman, M. S.; Curt, G. A.; Li, J.; Osmukhina, A.; Wu, K.; Huszar, D.; Borthukar, G.; Faderl, S.; Garcia-Manero, G.; Kadia, T.; Sankhala, K.; Odenike, O.; Altman, J. K.; Minden, M. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Invest. New Drugs, 2011, published online.